Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011).

Loh ML, Tasian SK, Rabin KR, Brown P, Magoon D, Reid JM, Chen X, Ahern CH, Weigel BJ, Blaney SM.

Pediatr Blood Cancer. 2015 Oct;62(10):1717-24. doi: 10.1002/pbc.25575. Epub 2015 May 13.

2.

A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report.

Kolb EA, Sampson V, Stabley D, Walter A, Sol-Church K, Cripe T, Hingorani P, Ahern CH, Weigel BJ, Zwiebel J, Blaney SM.

Pediatr Blood Cancer. 2015 May;62(5):751-8. doi: 10.1002/pbc.25464. Epub 2015 Feb 27.

3.

Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk.

Ahern CH, Shih YC, Dong W, Parmigiani G, Shen Y.

Br J Cancer. 2014 Oct 14;111(8):1542-51. doi: 10.1038/bjc.2014.458. Epub 2014 Aug 19.

4.

A phase I trial of MK-2206 in children with refractory malignancies: a Children's Oncology Group study.

Fouladi M, Perentesis JP, Phillips CL, Leary S, Reid JM, McGovern RM, Ingle AM, Ahern CH, Ames MM, Houghton P, Doyle LA, Weigel B, Blaney SM.

Pediatr Blood Cancer. 2014 Jul;61(7):1246-51. doi: 10.1002/pbc.25023. Epub 2014 Mar 24.

5.

A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112).

Thompson PA, Drissi R, Muscal JA, Panditharatna E, Fouladi M, Ingle AM, Ahern CH, Reid JM, Lin T, Weigel BJ, Blaney SM.

Clin Cancer Res. 2013 Dec 1;19(23):6578-84. doi: 10.1158/1078-0432.CCR-13-1117. Epub 2013 Oct 4.

6.

Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report.

Glade Bender JL, Lee A, Reid JM, Baruchel S, Roberts T, Voss SD, Wu B, Ahern CH, Ingle AM, Harris P, Weigel BJ, Blaney SM.

J Clin Oncol. 2013 Aug 20;31(24):3034-43. doi: 10.1200/JCO.2012.47.0914. Epub 2013 Jul 15.

7.

Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study.

Mossé YP, Lipsitz E, Fox E, Teachey DT, Maris JM, Weigel B, Adamson PC, Ingle MA, Ahern CH, Blaney SM.

Clin Cancer Res. 2012 Nov 1;18(21):6058-64. doi: 10.1158/1078-0432.CCR-11-3251. Epub 2012 Sep 17.

8.

A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916).

Muscal JA, Thompson PA, Horton TM, Ingle AM, Ahern CH, McGovern RM, Reid JM, Ames MM, Espinoza-Delgado I, Weigel BJ, Blaney SM.

Pediatr Blood Cancer. 2013 Mar;60(3):390-5. doi: 10.1002/pbc.24271. Epub 2012 Aug 9.

9.

Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group.

Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT, Reid JM, Schmechel S, Voss SD, Cho SY, Chen HX, Krailo MD, Adamson PC, Blaney SM.

J Clin Oncol. 2012 Jan 20;30(3):256-62. doi: 10.1200/JCO.2011.37.4355. Epub 2011 Dec 19.

10.

Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study.

DuBois SG, Shusterman S, Reid JM, Ingle AM, Ahern CH, Baruchel S, Glade-Bender J, Ivy P, Adamson PC, Blaney SM.

Cancer Chemother Pharmacol. 2012 Apr;69(4):1021-7. doi: 10.1007/s00280-011-1798-2. Epub 2011 Dec 18.

11.
12.

Routine nasogastric suction may be unnecessary after a pancreatic resection.

Fisher WE, Hodges SE, Cruz G, Artinyan A, Silberfein EJ, Ahern CH, Jo E, Brunicardi FC.

HPB (Oxford). 2011 Nov;13(11):792-6. doi: 10.1111/j.1477-2574.2011.00359.x. Epub 2011 Aug 1.

13.

Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.

Dubois SG, Shusterman S, Ingle AM, Ahern CH, Reid JM, Wu B, Baruchel S, Glade-Bender J, Ivy P, Grier HE, Adamson PC, Blaney SM.

Clin Cancer Res. 2011 Aug 1;17(15):5113-22. doi: 10.1158/1078-0432.CCR-11-0237. Epub 2011 Jun 20.

14.

Pancreatic resection without routine intraperitoneal drainage.

Fisher WE, Hodges SE, Silberfein EJ, Artinyan A, Ahern CH, Jo E, Brunicardi FC.

HPB (Oxford). 2011 Jul;13(7):503-10. doi: 10.1111/j.1477-2574.2011.00331.x.

15.

Down-regulation of ZIP4 by RNA interference inhibits pancreatic cancer growth and increases the survival of nude mice with pancreatic cancer xenografts.

Li M, Zhang Y, Bharadwaj U, Zhai QJ, Ahern CH, Fisher WE, Brunicardi FC, Logsdon CD, Chen C, Yao Q.

Clin Cancer Res. 2009 Oct 1;15(19):5993-6001. doi: 10.1158/1078-0432.CCR-09-0557. Epub 2009 Sep 15.

16.

Cost-effectiveness analysis of mammography and clinical breast examination strategies: a comparison with current guidelines.

Ahern CH, Shen Y.

Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):718-25. doi: 10.1158/1055-9965.EPI-08-0918. Epub 2009 Mar 3.

Supplemental Content

Loading ...
Support Center